Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in Chronic SIADH (SANDx)
NCT03202667Phase 3Completed
- Sponsor
- University Hospital Basel
- Start
- Dec 2017
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in syndrome of inappropriate antidiuresis (SIAD) and hyponatremia comparing Empagliflozin with Placebo (2 arms). Primary endpoint: Change in Serum Sodium concentration at 28 days. Started Dec 2017; status: completed.
02
Drugs
empagliflozin
03
Conditions
syndrome of inappropriate antidiuresis (SIAD)hyponatremia
Beyond the preview
Go deeper on NCT03202667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03202667.